Market research
BXRX Baudax Bio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 950K
- P/E ratio
- Not available
- Analyst target
- 24
- Dividend yield
- Not available
- Beta
- 1.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US07160F2065
- Market cap
- 950K
- P/E ratio
- Not available
- Analyst target
- 24
- Dividend yield
- Not available
- Beta
- 1.58
About
About Baudax Bio Inc
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BXRX discussion.
5 years, 4 months ago
Baudax Bio, Inc is currently in a long term downtrend where the price is trading 45.9% below its 200 day moving average.
From a valuation standpoint, the stock is 96.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 49.9.
Baudax Bio, Inc's total revenue rose by inf% to $76K since the same quarter in the previous year.
Its net income has dropped by 132.7% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 58.8% to $-15M since the same quarter in the previous year.
Based on the above factors, Baudax Bio, Inc gets an overall score of 2/5.